Drugs / Havrix
Havrix
also known as
Hepatitis A vaccine · HAV · Attenuated HAV Vaccine, L-A-1 Strain · Avaxim 80U Pediatric · Epaxal · GSK-208109 · HAV Vaccine · HAVRIX (1440 ELISA unit)per dose. · +2 more
Trials 34 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02376036 | Feb 2015 → Feb 2017 | — | MacroGenics | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02531698 | Aug 2015 → Mar 2017 | meningococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01339000 | Apr 2011 → Apr 2016 | breast cancer, colon carcinoma, urinary bladder cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01360970 | Sep 2009 → May 2011 | — | Lars Rombo | Completed | No outcome recorded |
| Phase 2 | NCT00621764 | Mar 2008 → Dec 2009 | Japanese encephalitis, hepatitis A virus infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00926419 | Jun → Nov 2009 | chickenpox, hepatitis A virus infection | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT03525119 | May → Oct 2018 | — | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT03537508 | Apr 2018 → Sep 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT02082639 | Feb → Aug 2015 | human papilloma virus infection | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 3 | NCT01352793 | Nov 2012 → Sep 2014 | meningococcal meningitis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01379937 | Jul 2011 → Aug 2012 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00839254 | Feb 2009 → Jan 2012 | pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00466947 | Jun 2007 → Aug 2010 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00197236 | Nov 2003 → Dec 2007 | hepatitis A virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00197015 | Oct 2003 → Jun 2009 | hepatitis A virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00197002 | Sep 2003 → Jan 2006 | hepatitis A virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00190242 | Jun 2003 → Oct 2006 | HIV infectious disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00057330 | Jan 2003 → Aug 2009 | herpes simplex infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 414 trials | ||||||
| Phase 4 | NCT06277882 | Feb 2024 → Mar 2025 | cirrhosis of liver, hepatitis A virus infection | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT06184230 | Jan 2024 → Mar 2025 | hepatitis A virus infection | Best Healthcare Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT03183492 | May 2018 → Jan 2019 | hepatitis A virus infection | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 4 | NCT03231605 | Jul → Aug 2017 | hepatitis A virus infection | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT03330171 | Apr 2017 → Feb 2019 | chickenpox, hepatitis A virus infection, measles | University of Witwatersrand, South Africa | Unknown | No outcome recorded |
| Phase 4 | NCT02011763 | Dec 2013 → Sep 2014 | hepatitis A virus infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01949857 | Sep 2013 → Dec 2015 | hepatitis A virus infection | Institute of Medical Biology, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01252680 | Apr 2010 → Feb 2011 | hepatitis A virus infection | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT01037114 | Jan 2010 → Feb 2014 | hepatitis A virus infection, hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01000324 | Nov 2009 → Jul 2014 | hepatitis A virus infection, hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00603252 | Jan → Jun 2008 | hepatitis A virus infection, hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00291876 | Jan 2004 → Mar 2013 | hepatitis A virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00289757 | Jan 2004 → Mar 2013 | hepatitis A virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00139113 | Sep 1996 → Jun 2001 | hepatitis A virus infection | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00001078 | ? → May 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00000943 | ? → Nov 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 48 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02296463 Background | Nov 2014 → Sep 2015 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT05084508 Background | Feb 2022 → Feb 2024 | chickenpox | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT04515147 Comparator | Sep 2020 → Feb 2022 | COVID-19, severe acute respiratory syndrome | CureVac | Completed | No outcome recorded |
| Phase 2 | NCT03917654 Comparator | Apr 2019 → Jul 2021 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02212457 Background | Aug 2014 → May 2015 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02038907 Background | Mar 2014 → Jun 2015 | — | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT01446978 Comparator | Sep 2011 → Aug 2016 | — | Sormland County Council, Sweden | Unknown | No outcome recorded |
| Phase 2 | NCT01282216 Comparator | Apr 2011 → Jan 2016 | cancer-related condition | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 2 | NCT00861744 Background | Jun 2009 → Jul 2010 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00880893 Comparator | Apr 2009 → Oct 2014 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00578175 Background | Nov 2007 → Feb 2009 | chickenpox, measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00513409 Background | Aug 2007 → Feb 2008 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00201448 Comparator | Jun 2007 → Oct 2009 | cytomegalovirus infection | Virginia Commonwealth University | Terminated | No outcome recorded |
| Phase 323 trials | ||||||
| Phase 3 | NCT06806137 Background | May 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06855160 Background | Apr 2025 → Sep 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06824181 Background | Feb 2025 → Sep 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06824194 Background | Feb 2025 → Oct 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06740630 Background | Jan 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06693895 Background | Nov 2024 → Nov 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT05794230 Background | Mar 2023 → Nov 2025 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT05012787 Comparator | Nov 2021 → Mar 2022 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Terminated | No outcome recorded |
| Phase 3 | NCT04704830 Background | Apr 2021 → Mar 2023 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03143218 Comparator | Apr 2017 → Mar 2020 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT01978093 Background | Feb 2014 → Mar 2016 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01830855 Comparator | Apr 2013 → Apr 2015 | meningococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01702428 Background | Nov 2012 → Nov 2014 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01681992 Background | Oct 2012 → Feb 2015 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01218308 Comparator | Dec 2010 → Jan 2012 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00861380 Comparator | May 2009 → Jan 2012 | pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00735644 Comparator | Aug 2008 → May 2009 | Japanese encephalitis, hepatitis A virus infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00624819 Background | Mar → Jun 2008 | pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00316706 Comparator | Oct 2005 → Jan 2009 | cervical intraepithelial neoplasia, human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00596271 Comparator | Sep 2005 → Jul 2006 | Japanese encephalitis | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00128661 Comparator | Jun 2004 → Dec 2010 | cervical cancer, precancerous condition | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00122681 Comparator | May 2004 → Nov 2006 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00224484 Comparator | Apr 2004 → Jul 2007 | herpes simplex infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT05543642 Comparator | Oct 2022 → Apr 2025 overdue | rheumatic disorder | Oregon Health and Science University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02583412 Comparator | Sep 2015 → Sep 2016 | meningococcal infection | Canadian Immunization Research Network | Completed | No outcome recorded |
| Phase 4 | NCT01824537 Comparator | Jan 2014 → Nov 2022 | human papilloma virus infection | McGill University | Completed | No outcome recorded |
| Phase 4 | NCT01349829 Comparator | Mar 2010 → Apr 2011 | hepatitis A virus infection | Crucell Holland BV | Completed | No outcome recorded |
| Phase 4 | NCT01028326 Comparator | Jan → Sep 2010 | streptococcal pneumonia | KEMRI-Wellcome Trust Collaborative Research Program | Unknown | No outcome recorded |
| Phase 4 | NCT00877396 Comparator | Sep 2008 → May 2011 | influenza | McMaster University | Completed | No outcome recorded |
| Phase 4 | NCT00684671 Comparator | May → Nov 2008 | hepatitis A virus infection, hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00534885 Comparator | Mar 2006 → Oct 2017 | hepatitis A virus infection | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT00289731 Comparator | Nov 2003 → Dec 2004 | hepatitis A virus infection, hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00125008 Comparator | May 2003 → Jan 2008 | paratyphoid fever, typhoid fever | International Vaccine Institute | Completed | No outcome recorded |
| Phase 4 | NCT00125047 Comparator | Oct 2001 → Aug 2007 | paratyphoid fever, typhoid fever | International Vaccine Institute | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01102296 Comparator | Jun 2009 → Mar 2012 | hepatitis | National Taiwan University Hospital | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 83 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Havrix | “Participants were randomly assigned (1:1) to receive an HPV vaccine (Cervarix, GlaxoSmithKline, Rixensart, Belgium) or a control hepatitis A vaccine (modified preparation of...” PMID 21865087 ↗ Aug 201151“GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine...” NCT00197015 ↗ “and Havrix™ (1440 EL.U) vaccine, administered intramuscularly in the right deltoid region, according to a 0 and 6 month schedule.” NCT00289731 ↗ “Subjects received one dose of Havrix at Day 0 followed by a second dose of Havrix at Month 6-9.” NCT00197236 ↗ “The control group will receive HAVRIX vaccine at month 0 and 6 and saline at month 2.” NCT01352793 ↗ “Hepatitis A vaccine (Epaxal or Havrix) were given at 0 and 6 months.” NCT01446978 ↗ “Havrix at 1440IU was administrated à weeks S0, S4 and S24” NCT00190242 ↗ “one dose of Havrix (hepatitis A vaccine, IM)” NCT00201448 ↗ “hepatitis A vaccine ( HAVRIX or EPAXAL)” NCT01360970 ↗ “a hepatitis A vaccine (Havrix)” NCT05084508 ↗ |
| Known as | Attenuated HAV Vaccine, L-A-1 Strain | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01949857 ↗ |
| Known as | Avaxim 80U Pediatric | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02011763 ↗ |
| Known as | Epaxal | “Hepatitis A vaccine (Epaxal or Havrix) were given at 0 and 6 months.” NCT01446978 ↗ |
| Known as | GSK-208109 | “GSK Biologicals' Hepatitis A Vaccine (Havrix®) (GSK-208109)” NCT02082639 ↗ |
| Known as | HAV | “HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration.” NCT03917654 ↗2“Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination” NCT00839254 ↗ “Biological: Havrix (HAV)” NCT01830855 ↗ |
| Known as | HAV Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03525119 ↗ |
| Known as | HAVRIX (1440 ELISA unit)per dose. | “HAVRIX (1440 ELISA unit)per dose.” NCT01102296 ↗ |
| Known as | Havrix TM | “GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)” NCT00861380 ↗ |
| Known as | Hepatitis A vaccine | “Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine” NCT00057330 ↗34“Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June)” NCT03143218 ↗ “Licensed pediatric hepatitis A vaccine” NCT02531698 ↗ |
| Known as | inactivated hepatitis A vaccine | “randomly assigned to receive a single dose of either Vi vaccine or inactivated hepatitis A vaccine” PMID 19625715 ↗ Jul 2009 |
| Modality | Vaccine | “hepatitis A vaccine” NCT00000943 ↗ |
| Route | Intramuscular | “the vaccine was administered intramuscularly in the non-dominant deltoid” NCT00057330 ↗ |